A systematic review of semaglutide-associated kidney injury case reports
-
By
-
Xian Xiu
-
Pan-pan Zheng
-
Yang Li
-
Meng Du
-
Xi Min
-
Xiaohua Pang
-
Lili Zhang
-
Jingtao Liu
-
Zhe Zhao
-
Zan-chao Liu
-
Cai-Xia Feng
-
June 1, 2026
-
Clinical Scorecard: A comprehensive analysis of reported cases of kidney injury linked to semaglutide use
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | GLP-1 receptor agonism affecting renal function (source needed) |
| Target Population | |
| Care Setting | Clinical settings prescribing semaglutide (source needed) |
Key Highlights
- 20 cases of kidney injury linked to semaglutide were analyzed.
- Adverse drug reactions included acute kidney injury, acute renal failure, and acute interstitial nephritis.
- Most patients had pre-existing medical conditions and were on concomitant medications.
- Kidney injury was diagnosed through renal biopsy or renal function parameters.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of kidney injury should consider renal function parameters and renal biopsy.
Management
- Clinicians should exercise caution when prescribing semaglutide to patients with underlying conditions (source needed).
Monitoring & Follow-up
- Regular monitoring of kidney function is recommended after initiating semaglutide treatment (source needed).
Risks
- Potential for irreversible kidney damage should be acknowledged (source needed).
Patient & Prescribing Data
Adults aged 29 to 83 years, predominantly with pre-existing conditions.
Semaglutide was administered via subcutaneous injection at doses ranging from 0.25 to 2.0 mg.
Clinical Best Practices
- Ensure thorough assessment of renal function before initiating semaglutide (source needed).
- Monitor for signs of kidney injury during treatment (source needed).
Related Resources & Content
